Zhejiang Shengda Bio-Pharm Co., Ltd. (SHA:603079)
China flag China · Delayed Price · Currency is CNY
11.42
-0.20 (-1.72%)
Nov 13, 2026, 3:00 PM CST

SHA:603079 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
813.82840.67826.61725.46736.96788.5
Other Revenue
2.533.870.791.941.061.23
816.35844.54827.4727.41738.02789.73
Revenue Growth
-2.79%2.07%13.75%-1.44%-6.55%-8.95%
Cost of Revenue
608.47634.9663.8653.22627.75573.41
Gross Profit
207.87209.64163.674.18110.27216.33
Selling, General & Admin
85.779.6276.7874.173.84104.28
Research & Development
51.8853.6743.7642.9237.4239.64
Other Operating Expenses
13.598.646.058.478.6311.02
Operating Expenses
151.42142.57132.06128.66120.34155.84
Operating Income
56.4567.0731.54-54.48-10.0760.49
Interest Expense
-0.05-0.91-2.08-1.54-4.56-5.76
Interest & Investment Income
5.6910.528.678.8115.2824.47
Currency Exchange Gain (Loss)
-3.2-2.444.13.8622.76-5.27
Other Non Operating Income (Expenses)
-9.46-0.23-0.21-0.3-0.3-0.77
EBT Excluding Unusual Items
49.4474.0142.02-43.6323.1173.16
Gain (Loss) on Sale of Investments
0.050.0500-0.90.01
Gain (Loss) on Sale of Assets
-0.92-0.480.150.20.090
Asset Writedown
-1.33-0.38-0.29-12.21-0.1-1.52
Legal Settlements
---8.1---
Other Unusual Items
7.026.9315.3110.3314.328.39
Pretax Income
54.2680.1349.09-45.3136.5280.04
Income Tax Expense
11.7510.8611.838.896.098.22
Earnings From Continuing Operations
42.5169.2637.26-54.230.4471.82
Minority Interest in Earnings
-8.57-7.11-7.830.141.053.93
Net Income
33.9462.1629.42-54.0631.4875.76
Net Income to Common
33.9462.1629.42-54.0631.4875.76
Net Income Growth
-44.44%111.24%---58.44%-61.63%
Shares Outstanding (Basic)
189178173169175172
Shares Outstanding (Diluted)
189178173169175172
Shares Change
4.30%2.60%2.45%-3.41%1.59%2.03%
EPS (Basic)
0.180.350.17-0.320.180.44
EPS (Diluted)
0.180.350.17-0.320.180.44
EPS Growth
-46.73%105.88%---59.09%-62.39%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
5.78-6.8-21.97-181.51-22.54-25.5
Free Cash Flow Per Share
0.03-0.04-0.13-1.07-0.13-0.15
Dividend Per Share
0.1000.100-0.0600.0600.140
Dividend Growth
---0%-57.14%-60.00%
Gross Margin
25.46%24.82%19.77%10.20%14.94%27.39%
Operating Margin
6.92%7.94%3.81%-7.49%-1.36%7.66%
Profit Margin
4.16%7.36%3.56%-7.43%4.27%9.59%
Free Cash Flow Margin
0.71%-0.80%-2.66%-24.95%-3.05%-3.23%
EBITDA
132.87142.49105.6417.5857.63131.39
EBITDA Margin
16.28%16.87%12.77%2.42%7.81%16.64%
D&A For EBITDA
76.4275.4374.172.0667.6970.9
EBIT
56.4567.0731.54-54.48-10.0760.49
EBIT Margin
6.92%7.94%3.81%-7.49%-1.36%7.66%
Effective Tax Rate
21.65%13.56%24.10%-16.66%10.27%
Revenue as Reported
223.25844.54827.4727.41738.02789.73
Advertising Expenses
-1.892.041.270.650.37